Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alvaro P. C. Lupinacci"'
Autor:
Graziela Massa, Resende, Alvaro P C, Lupinacci, Carlos Eduardo Leite, Árieta, Vital P, Costa, Vital, Costa
Publikováno v:
British Journal of Ophthalmology. 96:1190-1194
To investigate changes in central corneal thickness (CCT) and intraocular pressure (IOP) in children after congenital cataract surgery, as well as risk factors associated with these changes.37 eyes of 26 children with congenital cataract undergoing s
Autor:
Vance Zemon, Kevin Childers, Alvaro P. C. Lupinacci, Peter A. Netland, Sarwat Salim, George Hu
Publikováno v:
Documenta Ophthalmologica. 121:1-7
The purpose of this study was to assess the influence of pupil size and optical blur on measurements obtained with isolated-check visual evoked potential (icVEP). Two stimulus conditions of icVEP, +15 and −15% contrasts, were studied in normal subj
Autor:
Steve Charles, Alvaro P. C. Lupinacci, Mohammad Rafieetery, Peter A. Netland, Jorge I. Calzada
Publikováno v:
Advances in Therapy. 26:208-216
The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated with or without intravitreal bevacizumab.This was a retrospective, comparative case series of 60 patients with anterior segme
Publikováno v:
Decision Making in Ophthalmology: An Algorithmic Approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1c59a0b82cb847648aaaf751258d9c7
https://doi.org/10.5005/jp/books/12378_93
https://doi.org/10.5005/jp/books/12378_93
Publikováno v:
The Glaucoma Book ISBN: 9780387766997
Therapeutic efforts for treatment of glaucoma have focused on reduction of intraocular pressure as the main objective. In clinical practice, intraocular pressure (IOP) control has been expected to slow or arrest the glaucoma progression. However, cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abad685c1ed976db589afb7ebaa7ae16
https://doi.org/10.1007/978-0-387-76700-0_54
https://doi.org/10.1007/978-0-387-76700-0_54
Publikováno v:
Advances in therapy. 25(3)
Clinically, dorzolamide (Trusopt(R); MerckCo Inc, West Point, PA, USA) is often used twice daily (b.i.d.) or three times daily (t.i.d.) as adjunctive therapy with prostaglandins. Our purpose was to determine the effect of dorzolamide on intraocular p